The KRAS-G12C mutation, specifically, is identified in nearly one in seven patients. For decades KRAS was considered undruggable. As well as having very high affinity for its GTP/GDP substrates ...

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "A case of adenosquamous pancreatic ...

“Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.” ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...

Roche also axed a trial for divarasib, specifically a phase 2/3 trial that was comparing the KRAS G12C inhibitor to docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC).

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval to market its KRAS G12C ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

"We look forward to presenting an update to our growing body of preclinical and clinical data that demonstrate the potential of KO-2806 as a companion therapeutic to augment the antitumor activities ...